Leukemia research · 2013
Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Watanabe Reina, Tomita Naoto, Kishimoto Kumiko, Koyama Satoshi, Ogusa Eriko, Ishii Yoshimi, Miyashita Kazuho, Matsuura Shiro, Fujisawa Shin, Hattori Yukako, Takasaki Hirotaka, Fujita Atsuko, Ohshima Rika, Kuwabara Hideyuki, Hashimoto Chizuko, Fujimaki Katsumichi, Sakai Rika, Ishigatsubo Yoshiaki
Аннотация
Elevated absolute monocyte counts (AMCs) have been reported to indicate poor prognosis for patients with lymphoproliferative disease, including those with follicular lymphoma (FL) receiving various treatments. We evaluated the prognostic impact of AMC in 150 consecutive FL patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Progression-free survival (PFS) did not differ significantly according to the AMC level. Univariate and multivariate analyses did not indicate a prognostic significance of AMC for PFS. Thus, the AMC is not a prognostic factor for FL patients treated with R-CHOP. However, immunochemotherapy might influence the prognostic impact of AMC.